This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer
by Zacks Equity Research
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
NVOPositive Net Change LLYNegative Net Change VRTXNegative Net Change
biotechs medical pharmaceuticals
RCKT Stock Tanks on Patient Death in Danon Disease Study
by Zacks Equity Research
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
LXRXPositive Net Change AMRNPositive Net Change RCKTNegative Net Change CMMBNegative Net Change
biotechs
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
by Zacks Equity Research
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
BAYRYNegative Net Change LXRXPositive Net Change AMRNPositive Net Change VSTMPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
by Ekta Bagri
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
GRFSNegative Net Change ADMANo Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
by Sundeep Ganoria
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals vaccines
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
AZNNegative Net Change HALONegative Net Change LXRXPositive Net Change AMRNPositive Net Change
biotechs
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
by Zacks Equity Research
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
RHHBYNegative Net Change BMYNegative Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs medical pharmaceuticals
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
by Ahan Chakraborty
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
SNYNegative Net Change LLYNegative Net Change SDGRNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
by Zacks Equity Research
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
GSKNegative Net Change HALONegative Net Change LXRXPositive Net Change AMRNPositive Net Change
biotechs
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
by Zacks Equity Research
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
HALONegative Net Change LXRXPositive Net Change AMRNPositive Net Change
biotechs
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
by Zacks Equity Research
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.
AZNNegative Net Change RHHBYNegative Net Change PFENegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
by Zacks Equity Research
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
NVSNegative Net Change PFENegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
NVOPositive Net Change LLYNegative Net Change CRBPNo Net Change SKYENegative Net Change
biotechs marijuana medical pharmaceuticals
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
by Zacks Equity Research
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
REGNNegative Net Change BAYRYNegative Net Change HALONegative Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
by Zacks Equity Research
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
BMYNegative Net Change BAYRYNegative Net Change EXELPositive Net Change AMRNPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Is it a Good Idea to Invest in Immunocore Stock Right Now?
by Zacks Equity Research
IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.
BMYNegative Net Change CRMDNegative Net Change IMCRNegative Net Change
biotechs
FDA Approves GSK's Nucala for Expanded Use in COPD
by Zacks Equity Research
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
REGNNegative Net Change SNYNegative Net Change GSKNegative Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
by Ekta Bagri
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
BMRNNegative Net Change MRNANegative Net Change NVAXNegative Net Change PRMENegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
by Zacks Equity Research
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
by Zacks Equity Research
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
JNJNegative Net Change MRKNegative Net Change IBRXPositive Net Change CGONPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ARMP Soars 72% in a Month Following Infectious Disease Study Success
by Zacks Equity Research
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
BAYRYNegative Net Change HALONegative Net Change AMRNPositive Net Change ARMPNegative Net Change
biotechnology biotechs medical pharmaceuticals
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
by Kinjel Shah
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
JNJNegative Net Change NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
by Sundeep Ganoria
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines